Keyphrases
ADI-PEG20
15%
Advanced Soft Tissue Sarcoma
21%
Adverse Events
20%
Angiosarcoma
12%
Arginine
14%
Arginine Starvation
13%
Argininosuccinate Synthetase
16%
Cancer Genome Atlas
33%
Cancer Types
39%
Chemotherapy
17%
Clinical Outcomes
14%
Clinical Trials
20%
Comprehensive Characterization
11%
Confidence Interval
16%
Dacarbazine
17%
Dedifferentiated Liposarcoma (DDLPS)
15%
Desmoid Tumor
11%
Docetaxel
11%
Doxorubicin
37%
Duration of Response
12%
Gemcitabine
12%
Glyceraldehyde-3-phosphate Dehydrogenase
11%
High-risk Human Papillomavirus (HR-HPV)
17%
Human Cancer
12%
In Cancer
17%
Leiomyosarcoma
25%
Liposarcoma
12%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
18%
Metastatic Sarcoma
14%
Metastatic Soft Tissue Sarcoma
19%
Molecular Characterization
11%
Myxoid
17%
Olaratumab
17%
Osteosarcoma
23%
Overall Survival
17%
Pan-cancer
16%
Pan-cancer Analysis
11%
Partial Response
12%
Patient-derived Xenograft
13%
Pazopanib
15%
Phase II Study
40%
Phase II Trial
38%
Progression-free Survival
21%
Radiation Therapy
15%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Round Cell Liposarcoma
17%
Sarcoma
84%
Soft Tissue Sarcoma
73%
Synovial Sarcoma
40%
Tumor
59%
Medicine and Dentistry
Adverse Event
23%
Angiosarcoma
15%
Anthracycline
7%
Arginine
22%
Argininosuccinate Synthase
7%
Arm
15%
Biological Marker
11%
Breast Cancer
6%
Cancer
26%
Cancer Types
13%
Carcinogenesis
6%
Cell Signaling Pathway
8%
Clinical Trial
32%
Connective Tissue Cancer
100%
Dacarbazine
14%
Dedifferentiated Liposarcoma
7%
Desmoid Tumor
11%
Diseases
24%
Docetaxel
8%
Doxorubicin
19%
Ewing Sarcoma
6%
Gastrointestinal Stromal Tumor
14%
Gemcitabine
8%
HLA-A
7%
Ifosfamide
10%
Immunotherapy
14%
Ipilimumab
6%
Leiomyosarcoma
24%
Liposarcoma
11%
Liposarcoma Cell
16%
Malignant Neoplasm
38%
Malignant Peripheral Nerve Sheath Tumor
9%
Neoplasm
54%
Neutropenia
6%
Nivolumab
6%
Olaratumab
9%
Osteosarcoma
15%
Overall Survival
23%
Pazopanib
12%
Pembrolizumab
9%
Placebo
6%
Progression Free Survival
25%
Radiation Therapy
14%
Soft Tissue Sarcoma
79%
Synovial Sarcoma
31%
Systemic Therapy
7%
T Cell
11%
Targeted Therapy
9%
The Cancer Genome Atlas
16%
Trabectedin
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
27%
Angiosarcoma
11%
Anthracycline
6%
Arginine
17%
Argininosuccinate Synthase
6%
Atezolizumab
5%
Biological Marker
14%
Cardiotoxicity
6%
Chemotherapy
18%
Clinical Study
5%
Clinical Trial
18%
Connective Tissue Cancer
53%
Dacarbazine
17%
Dedifferentiated Liposarcoma
11%
Desmoid Tumor
5%
Diseases
25%
Docetaxel
11%
Doxorubicin
37%
Evofosfamide
5%
Gastrointestinal Stromal Tumor
7%
Gemcitabine
12%
Head and Neck Squamous Cell Carcinoma
6%
Human Papillomavirus
11%
Ipilimumab
5%
Leiomyosarcoma
19%
Liposarcoma
16%
Malignant Neoplasm
42%
Malignant Peripheral Nerve Sheath Tumor
8%
Monotherapy
7%
Neoplasm
45%
Neutropenia
6%
Nivolumab
5%
Olaratumab
17%
Osteosarcoma
12%
Ovary Cancer
5%
Overall Survival
24%
Palbociclib
5%
Pazopanib
15%
Perivascular Epithelioid Cell Tumour
5%
Pexidartinib
5%
Pharmacokinetics
7%
Phase II Trials
6%
Placebo
11%
Progression Free Survival
37%
Proteinase
6%
Rapamycin
11%
Soft Tissue Sarcoma
68%
Solid Malignant Neoplasm
9%
Synovial Sarcoma
18%
Trabectedin
9%